The DOI matches its Crossref record; 52 of the 55 references it cites were found in a registry or an index.
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
Abstract
Context Bladder cancer has become a common cancer globally, with an estimated 430 000 new cases diagnosed in 2012. Objective We examine the most recent global bladder cancer incidence and mortality patterns and trends, the current understanding of the aetiology of the disease, and specific issues that may influence the registration and reporting of bladder cancer. Evidence acquisition Global bladder cancer incidence and mortality statistics are based on data from the International Agency for Research on Cancer and the World Health Organisation (Cancer Incidence in Five Continents, GLOBOCAN, and the World Health Organisation Mortality). Evidence synthesis Bladder cancer ranks as the ninth most frequently-diagnosed cancer worldwide, with the highest incidence rates observed in men in Southern and Western Europe, North America, as well in certain countries in Northern Africa or Western Asia. Incidence rates are consistently lower in women than men, although sex differences varied greatly between countries. Diverging incidence trends were also observed by sex in many countries, with stabilising or declining rates in men but some increasing trends seen for women. Bladder cancer ranks 13th in terms of deaths ranks, with mortality rates decreasing particularly in the most developed countries; the exceptions are countries undergoing rapid economic transition, including in Central and South America, some central, southern, and eastern European countries, and the Baltic countries. Conclusions The observed patterns and trends of bladder cancer incidence worldwide appear to reflect the prevalence of tobacco smoking, although infection with Schistosoma haematobium and other risk factors are major causes in selected populations. Differences in coding and registration practices need to be considered when comparing bladder cancer statistics geographically or over time. Patient summary The main risk factor for bladder cancer is tobacco smoking. The observed patterns and trends of bladder cancer incidence worldwide appear to reflect the prevalence of tobacco smoking.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The epidemiology of bladder cancer varies by region, with tobacco smoking, occupational exposures (e.g., aromatic amines), and arsenic contamination of drinking water among the putative causes in industrialized countries.159,160”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
In the citing paper
“Diverging bladder cancer incidence trends have been observed by sex since the 1990s, with rates tending to decrease or stabilize in men but increase among women in certain European countries (e.g., in Spain, the Netherlands, Germany, and Belarus).160,162,163”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
In the citing paper
“comparing trends in bladder cancer mortality rates may be more suitable for assessing progress in disease control.160,166”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
In the citing paper
“Of note, there may be artifactual changes in incidence because of differences in coding and registration practice concerning inclusion or otherwise of noninvasive carcinomas.160,166,167”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
In the citing paper
“increases in mortality rates have also been reported among men in Thailand, Israel, and Slovakia and among women in Thailand, Japan, Croatia, and Poland.160”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Self-citationCancer Incidence in Five Continents
Doll, R., Muir, C. S., & Waterhouse, J. A. H. (1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,485
The United Nations Development Programme
Oestreich, J. E. (2017) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780190637347.003.0003 · Cited by 4,875
The global health burden of infection‐associated cancers in the year 2002
Parkin, D. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21731 · Cited by 2,932
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
Babjuk, M. M., Andreas Böhle, E., Burger, M., Čapoun, O., Cohen, D. L., Compérat, É., Hernández, V., KAASINEN, E. S., Palou, J., Morgan Rouprêt, A., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.05.041 · Cited by 2,240
Epidemiology and Risk Factors of Urothelial Bladder Cancer
Burger, M., Catto, J. W. F., Dalbagni, G. M., Grossman, H. B., Herr, H. W., Karakiewicz, P. I., Kassouf, W., Kiemeney, L. A. L. M., Vecchia, C. L., Shariat, S. F., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.07.033 · Cited by 2,212
Steinmann, P., Keiser, J., Bos, R., Tanner, M., & Utzinger, J. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70521-7 · Cited by 2,146
Smoking prevalence and cigarette consumption in 187 countries, 1980-2012
Ng, M., Freeman, M. K., Fleming, T. D., Robinson, M., Dwyer-Lindgren, L., Thomson, B., Wollum, A., Sanman, E., Wulf, S., Lopez, A. D., et al. (2014) · JAMA · doi:10.1001/jama.2013.284692 · Cited by 1,576
Estimating average annual per cent change in trend analysis
Clegg, L. X., Hankey, B. F., Tiwari, R. C., Feuer, E. J., & Edwards, B. K. (2009) · Statistics in Medicine · doi:10.1002/sim.3733 · Cited by 1,271
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
Babjuk, M., Burger, M., Zigeuner, R., Shariat, S. F., van Rhijn, B. W. G., Compérat, E., Sylvester, R. J., Kaasinen, E., Böhle, A., Palou Redorta, J., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.06.003 · Cited by 1,174
Research works printed but not linked: 1
- Loader C. Smoothing: Local Regression Techniques Web site. http://hdl.handle.net/10419/22186.
Cited by
Sorted by citations
Items 701–800 of 1,000
A Pre-operative Nomogram for Prediction of Lymph Node Metastasis in Bladder Urothelial Carcinoma
Lu, X., Wang, Y., Jiang, L., Gao, J., Zhu, Y., Hu, W., Wang, J., Ruan, X., Xu, Z., Meng, X., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00488 · Cited by 20
Optical biopsy of bladder cancer using confocal laser endomicroscopy
Wu, J., Wang, Y.-C., Dai, B., Ye, D., & Zhu, Y. (2019) · International Urology and Nephrology · doi:10.1007/s11255-019-02197-z · Cited by 20
MicroRNA‐769‐5p suppresses cell growth and migration via targeting NUSAP1 in bladder cancer
Chen, Y., Zhang, W., Kadier, A., Zhang, H., & Yao, X. (2020) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23193 · Cited by 20
RetractedAdamkiewicz, M., Bryniarski, P., Kowalik, M., Burzyński, B., Rajwa, P., & Paradysz, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.655000 · Cited by 20
Xiong, Y., Zu, X., Wang, L., Li, Y., Chen, M., He, W., & Qi, L. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01841-y · Cited by 20
Knockdown of MCM8 inhibits development and progression of bladder cancer in vitro and in vivo
Zhu, W., Gao, F., Zhou, H., Jin, K., Shao, J., & Xu, Z. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01948-2 · Cited by 20
Downregulation of CacyBP by CRISPR/dCas9-KRAB Prevents Bladder Cancer Progression
Zheng, H., & Chen, C. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.692941 · Cited by 20
Kufukihara, R., Kikuchi, E., Shigeta, K., Ogihara, K., Arita, Y., Akita, H., Suzuki, T., Abe, T., Mizuno, R., Jinzaki, M., et al. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.07.005 · Cited by 20
Lai, G., Zhong, X., Liu, H., Deng, J., Li, K., & Xie, B. (2022) · Cancers · doi:10.3390/cancers14215346 · Cited by 21
PABPN1 regulates mRNA alternative polyadenylation to inhibit bladder cancer progression
Chen, L., Dong, W., Zhou, M., Yang, C., Xiong, M., Kazobinka, G., Chen, Z., Xing, Y., & Hou, T. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-00997-6 · Cited by 20
Smart, A., Liu, K. X., Domogauer, J., Rodriguez-Russo, C. A., Jones, B. M., Dickstein, D. R., Mancias, J. D., Shiloh, R. Y., Wintner, A., Zietman, A. L., et al. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.05.028 · Cited by 20
Role of human papillomavirus and associated viruses in bladder cancer: An updated review
Yao, X., Xu, Z., Duan, C., Zhang, Y., Wu, X., Wu, H., Liu, K., Mao, X., Li, B., Gao, Y., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29088 · Cited by 20
Boll, L. M., Perera‐Bel, J., Rodríguez‐Vida, A., Arpí, O., Rovira, A., Juanpere-Rodero, N., de Oca, S. V. M., Hernández‐Llodrà, S., Lloreta, J., Albà, M. M., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-42495-2 · Cited by 21
Identification of differentially expressed genes and biological pathways in bladder cancer
Tang, F., He, Z., Lei, H., Chen, Y., Lu, Z., Zeng, G., & Wang, H. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8711 · Cited by 20
Lee, Y., & Lin, Y. (2018) · Nanomaterials · doi:10.3390/nano8050283 · Cited by 20
Mano, R., Zilber, S., DiNatale, R. G., Kedar, D. J., Lifshitz, D. A., Yossepowitch, O., Baniel, J., & Margel, D. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.09.007 · Cited by 20
Mathis, C., Lascombe, I., Monnien, F., Bittard, H., Kleinclauss, F., Bedgedjian, I., Fauconnet, S., & Valmary‐Degano, S. (2018) · BMC Cancer · doi:10.1186/s12885-018-5137-4 · Cited by 20
Tsai, Y., Jou, Y., Tsai, H., Shiau, A., Wu, C., & Tzai, T. (2019) · Cancer Science · doi:10.1111/cas.13963 · Cited by 20
The impact of postoperative inflammatory biomarkers on oncologic outcomes of bladder cancer
Albisinni, S., Moussa, I., Aoun, F. Y., Quackels, T., Assenmacher, G., Peltier, A., & Roumeguère, T. (2019) · The French Journal of Urology · doi:10.1016/j.purol.2019.02.008 · Cited by 20
Tumor Budding: Prognostic Value in Muscle-invasive Bladder Cancer
Soriano, L. L., Jurado, G. O., Moreno, J. L. P., Castillo, S. V., Girón, S. H., Moreno, I. S., & Soler, D. R. (2019) · Urology · doi:10.1016/j.urology.2019.04.006 · Cited by 20
Causes of death in long‐term bladder cancer survivors: A population‐based study
Kong, J., Diao, X., Diao, F., Fan, X., Zheng, J., Yan, D., Huang, J., Qin, H., & Lin, T. (2019) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13156 · Cited by 20
Xu, X. (2019) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-19-0604 · Cited by 20
Chen, C., Huang, H., Zhao, Y., Liu, H., Sylvester, R. J., Lin, T., & Huang, J. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028173 · Cited by 21
Tobacco smoking and death from prostate cancer in US veterans
Riviere, P. J., Kumar, A., Luterstein, E., Vitzthum, L. K., Nalawade, V. V., Sarkar, R. R., Bryant, A. K., Einck, J. P., Mundt, A. J., Murphy, J. D., et al. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0178-6 · Cited by 20
Therapeutic Effects of Curcumin against Bladder Cancer: A Review of Possible Molecular Pathways.
Ashrafizadeh, M., Yaribeygi, H., & Sahebkar, A. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200203143803 · Cited by 18
Dunsmore, J., Duncan, E., Mariappan, P., de Bruin, M., MacLennan, S. J., Dimitropoulos, K., Kasivisvanathan, V., Mostafid, H. A., Briganti, A., N’Dow, J., et al. (2021) · British Journal of Urology · doi:10.1111/bju.15336 · Cited by 20
Ye, Z., Chen, J., Hong, Y. K., Xin, W., Yang, S., & Rao, Y. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s170477 · Cited by 20
Hong, X., Xu, Q., Lan, K., Huang, H. L., Zhang, Y., Chen, S., Chi, Z., Lin, J., Zhou, Y., Wu, W., et al. (2018) · Nutrition and Cancer · doi:10.1080/01635581.2018.1512636 · Cited by 20
Schulz, G. B., Grimm, T., Büchner, A., Jokisch, F., Kretschmer, A., Stief, C. G., Knüchel, R., Kraywinkel, K., & Karl, A. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.10.008 · Cited by 20
Basu, M., Ghosh, S., Roychowdhury, A., Samadder, S., Das, P. K., Addya, S., Roy, A. K., Pal, D. K., Roychoudhury, S., Ghosh, A., et al. (2020) · Genomics · doi:10.1016/j.ygeno.2020.09.012 · Cited by 19
Estrogen receptor-β signaling induces cisplatin resistance in bladder cancer.
Goto, T., Kashiwagi, E., Jiang, G., Nagata, Y., Teramoto, Y., Baras, A. S., Yamashita, S., Ito, A., Arai, Y., & Miyamoto, H. (2020) · PubMed Central · Cited by 19
Primary cilia presence and implications in bladder cancer progression and invasiveness
Iruzubieta, P., Castiella, T., Monleón, E., Berga, C., Muñoz, G., & Junquera, C. (2021) · Histochemistry and Cell Biology · doi:10.1007/s00418-021-01965-2 · Cited by 20
Gao, R., Wen, R., Wen, D., Huang, J., Qin, H., Li, X., Wang, X., He, Y., & Yang, H. (2021) · Journal of Ultrasound in Medicine · doi:10.1002/jum.15659 · Cited by 19
Xu, X., Wang, H. J., Guo, Y., Zhang, X., Baojuan Li, A., Du, P., Liu, Y., & Lu, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.704039 · Cited by 19
SLC25A21 Suppresses Cell Growth in Bladder Cancer via an Oxidative Stress-Mediated Mechanism
Wang, Y., Gao, J.-W., Hu, S., Zeng, W., Yang, H., Chen, H., & Wang, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682710 · Cited by 19
Khazaei, S., Shirzadi, M. R., Mohammadi, P. M., Moradi, G., Goodarzi, E., Moayed, L., & Khazaei, Z. (2020) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2021.62.3.1699 · Cited by 21
CD274 (PD-L1) Methylation is an Independent Predictor for Bladder Cancer Patients’ Survival
Xu, J., Wei, L., Liu, H., Yu, L., Zhu, Y., Liang, C. Y., & Sun, G. (2022) · Cancer Investigation · doi:10.1080/07357907.2022.2028805 · Cited by 19
Lin, N., Chen, L., Zhang, Y., Yang, Y., Zhang, L., Chen, L., Zhang, P., Su, H., & Yin, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-10029-x · Cited by 19
RetractedThe Additional Value of Tri-parametric MRI in Identifying Muscle-invasive Status in Bladder Cancer
Liu, Y., Xu, X., Wang, H. J., Liu, Y., Wang, Y., Dong, Q., Li, Z., Guo, Y., & Lu, H. (2022) · Academic Radiology · doi:10.1016/j.acra.2022.04.014 · Cited by 19
Rao, X., Cao, H., Yu, Q., Ou, X., Deng, R., & Huang, J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.892535 · Cited by 19
Deng, Y., Wu, T., Luo, G., & Chen, L. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.992599 · Cited by 19
Muhsin, M. A., Wang, X., Kabole, F. M., Zilabumba, J., & Yang, K. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7110347 · Cited by 19
SPHK1 promotes bladder cancer metastasis via PD-L2/c-Src/FAK signaling cascade
Kao, W.-H., Liao, L.-Z., Chen, Y., Lo, U., Pong, R.-C., Hernandez, E., Chen, M., Teng, C. J., Wang, H., Tsai, S. C., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07044-3 · Cited by 19
Tzelves, L. I., Skolarikos, A. A., Mourmouris, P., Lazarou, L. C., Κωστακόπουλος, Ν., Manatakis, D. K., & Kural, A. R. (2019) · Journal of Endourology · doi:10.1089/end.2019.0226 · Cited by 19
Suh, J., Moon, K. C., Jung, J. H., Lee, J., Song, W. H., Kang, Y. J., Jeong, C. W., Kwak, C. H., Kim, H. H., & Ku, J. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-51889-0 · Cited by 19
Epidemiology and unmet needs of bladder cancer in Italy: a critical review
Nunzio, C. D., Giannatempo, P., Passalacqua, R., Fiorini, E., Luccarini, I., & Brigido, A. (2020) · Minerva Urologica e Nefrologica · doi:10.23736/s0393-2249.19.03498-2 · Cited by 19
DNA Methylation and Bladder Cancer: Where Genotype does not Predict Phenotype
Sharma, A., Reutter, H. M., & Ellinger, J. (2020) · Current Genomics · doi:10.2174/1389202921666200102163422 · Cited by 19
Abufaraj, M. M., Shariat, S. F., Moschini, M., Rohrer, F., Papantoniou, K., Devore, E. E., McGrath, M., Zhang, X., Markt, S. C., & Schernhammer, E. S. (2019) · International Journal of Epidemiology · doi:10.1093/ije/dyz264 · Cited by 19
Chung, J., Kulkarni, G. S., Bender, J. L., Breau, R. H., Guttman, D. M., Maganti, M. D., Matthew, A., Morash, R., Papadakos, J., & Jones, J. M. (2020) · British Journal of Urology · doi:10.1111/bju.15007 · Cited by 19
Wang, C., Yang, S., Jin Wei, L. U., Dai, G., Qiu, Y., Xiang, H., Zhang, Y., Liu, X., & Xue, B. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s237099 · Cited by 19
Puerarin Inhibits the Progression of Bladder Cancer by Regulating circ_0020394/miR-328-3p/NRBP1 Axis
Du, L., Zhang, L., & Sun, F. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2019.3382 · Cited by 19
Genomic Instability Signature of Palindromic Non-Coding Somatic Mutations in Bladder Cancer
Vacher, S., Suybeng, V., Girard, E., Masliah‐Planchon, J., Thomson, G. J., Goux, C., Garinet, S., Schnitzler, A., Chemlali, W., Firlej, V., et al. (2020) · Cancers · doi:10.3390/cancers12102882 · Cited by 19
Li, F., Yang, J., Shen, C., Wu, Z., & Hu, H. (2021) · Acta Histochemica · doi:10.1016/j.acthis.2021.151745 · Cited by 19
Yang, Z., Sun, H., Ma, W., Wu, K., Peng, G., Ou, T., & Wu, S. (2021) · FEBS Open Bio · doi:10.1002/2211-5463.13262 · Cited by 19
Ma, M., Zhang, P., Liang, X., Cui, D., Shao, Q., Zhang, H., Zhang, M., Yang, T., Wang, L., Zhang, N., et al. (2021) · Nano Research · doi:10.1007/s12274-021-3807-z · Cited by 19
Frączek, M., Kamecki, H., Kamecka, A., Sosnowski, R., Sklinda, K., Czarniecki, M., Królicki, L., & Walecki, J. M. (2018) · Translational Andrology and Urology · doi:10.21037/tau.2018.08.28 · Cited by 19
Molenaar, R. J., van Hattum, J. W., Brummelhuis, I. S. G., Oddens, J. R., Savci-Heijink, C. D., Boevé, E. R., van der Meer, S. A., Witjes, J., Pollak, M., de Reijke, T. M., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6346-1 · Cited by 19
Chen, Q., Li, L., Wang, G., Hu, J., Sun, T., & Fu, B. (2017) · Oncotarget · doi:10.18632/oncotarget.17593 · Cited by 18
A glance at imaging bladder cancer
Salmanoğlu, E., Halpern, E. J., Trabulsi, E., Kim, S. H., & Thakur, M. L. (2018) · Clinical and Translational Imaging · doi:10.1007/s40336-018-0284-9 · Cited by 18
LncRNA-ATB in cancers: what do we know so far?
Tang, F. R., Xu, Y., Wang, H., Bian, E., & Zhao, B. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05415-5 · Cited by 17
Hektoen, H. H., Robsahm, T. E., Andreassen, B. K., Stenehjem, J. S., Axcrona, K., Mondul, A. M., & Gislefoss, R. E. (2020) · Cancer Medicine · doi:10.1002/cam4.3060 · Cited by 19
Roles of N6‐methyladenosine (m6A) RNA modifications in urological cancers
Wang, X., Xie, H., Ying, Y., Chen, D., & Li, J. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15750 · Cited by 19
Taubert, H. W., Eckstein, M., Epple, E., Jung, R., Weigelt, K., Lieb, V., Sikic, D., Stöhr, R., Geppert, C. I., Weyerer, V., et al. (2021) · Cells · doi:10.3390/cells10010159 · Cited by 18
Kumawat, G., Vyas, N., Govind, S., Priyadarshi, S., Sahay, G. B., Mohit, S., & Ashok, K. (2021) · Asian journal of urology · doi:10.1016/j.ajur.2021.06.001 · Cited by 18
Feng, C., Wang, X., Tao, Y., Xie, Y., Lai, Z., Li, Z., Hu, J., Tang, S., Pan, L.-X., He, L., et al. (2021) · Cancers · doi:10.3390/cancers13215440 · Cited by 18
Chen, K., Ji, X., Yu, W., Xia, Y., Zhang, Y., Fan, C., & Rao, T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.782981 · Cited by 18
Franza, A., Pirovano, M., Giannatempo, P., & Cosmai, L. (2022) · Future Oncology · doi:10.2217/fon-2021-1151 · Cited by 18
The Emerging Roles and Clinical Potential of circSMARCA5 in Cancer
Xue, C., Wei, J., Li, M., Chen, S., Zheng, L., Zhan, Y., Duan, Y., Deng, H., Xiong, W., Li, G., et al. (2022) · Cells · doi:10.3390/cells11193074 · Cited by 18
Arita, Y., Kwee, T. C., Woo, S., Shigeta, K., Ishii, R., Okawara, N., Edo, H., Waseda, Y., & Vargas, H. A. (2023) · European Urology Focus · doi:10.1016/j.euf.2023.08.004 · Cited by 18
Liu, T., Fan, M., Xie, X., Shu, Q.-P., Du, X., Qi, L.-Z., Zhang, X., Zhang, M., Shan, G., Du, R.-L., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04311-3 · Cited by 18
Wu, J., Guo, Q., Li, J., Yuan, H., Xiao, C., Qiu, J., Wu, Q., & Wang, D. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115870 · Cited by 18
Huang, C., Yang, Y., Wang, X., Chen, S., Liu, Z., Li, Z., Tang, X., & Zhang, Q. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.96671 · Cited by 18
ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer
Owczarek, T. B., Kobayashi, T., Ramirez, R. J., Rong, L., Puzio‐Kuter, A. M., Iyer, G., Teo, M. Y., Sánchez-Vega, F., Wang, J., Schultz, N. D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2621 · Cited by 19
Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer
Aydın, A. M., Woldu, S. L., Hutchinson, R. C., Boegemann, M., Bagrodia, A., Lotan, Y., Margulis, V., & Krabbe, L. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s109453 · Cited by 18
Toward personalized management in bladder cancer: the promise of novel molecular taxonomy
Eich, M., Dyrskjøt, L., & Netto, G. J. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2119-x · Cited by 18
Erichsen, L., Ghanjati, F., Beermann, A., Poyet, C., Hermanns, T., Schulz, W. A., Seifert, H., Wild, P. J., Buser, L., Kröning, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21932-7 · Cited by 18
Yadav, D., Mishra, B. N., & Khan, F. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1528888 · Cited by 18
Huang, H., Yan, B., Shang, M., Liu, L., Hao, H., & Xi, Z. (2019) · BMC Urology · doi:10.1186/s12894-019-0461-9 · Cited by 18
KIF5A Promotes Bladder Cancer Proliferation In Vitro and In Vivo
Tian, D., Wu, Z., Jiang, L., Gao, J., Wu, C., & Hu, H. (2019) · Disease Markers · doi:10.1155/2019/4824902 · Cited by 18
RetractedHu, G., Xiu, W., Han, Y., & Wang, P. (2018) · EXCLI journal · doi:10.17179/excli2018-1719 · Cited by 18
Jin, D., Qiu, S., Jin, K., Zhou, X., Cao, Q., Yang, L., & Wei, Q. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00653 · Cited by 18
Loss of E-cadherin expression in recurrent non-invasive urothelial carcinoma of the bladder.
Balcı, M. G., & Tayfur, M. (2018) · Europe PMC (PubMed Central) · Cited by 18
Wang, F., Liu, P., An, H., & Zhang, Y. L. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4665 · Cited by 18
Xu, N., Lin, W., Sun, J., Sadahira, T., Xu, X., Watanabe, M., Guo, K. X., Araki, M., Li, G., Liu, C., et al. (2020) · Journal of Cancer · doi:10.7150/jca.47025 · Cited by 18
Huang, J., & Teng, X. (2020) · Current Oncology · doi:10.3747/co.27.6437 · Cited by 19
Sun, X., Zhou, Z., Zhang, Y., Wang, J., Zhao, X., Jin, L., Zhai, T., Liu, X., Zhang, J., Mei, W., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01954-4 · Cited by 18
Shi, H., Zhang, W., Bi, X., Wang, D., Xiao, Z., Guan, Y., Guan, K., Tian, J. Q., Bai, H., Hu, L., et al. (2021) · Cancer Research and Treatment · doi:10.4143/crt.2020.1356 · Cited by 18
Chen, Y., Wang, H.-H., Chang, H., Huang, Y.-H., Wang, J. R., Changchien, C., & Wu, S. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153587 · Cited by 18
Tang, C., Yu, M., Ma, J., & Zhu, Y. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02865-8 · Cited by 20
HSP47 contributes to angiogenesis by induction of CCL2 in bladder cancer
Ma, W., Ou, T., Cui, X., Wu, K., Li, H., Li, Y., Peng, G., Xia, W., & Wu, S. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110044 · Cited by 18
A novel self-learning framework for bladder cancer grading using histopathological images
García, G., Esteve, A., Colomer, A., Ramos, D., & Naranjo, V. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104932 · Cited by 18
Zhang, Q., Liu, Y., Chen, P., Shi, X., Ying, L., Shi, L., Cong, P., Mao, S., Tong, C.-C., Du, C., et al. (2021) · Bioengineered · doi:10.1080/21655979.2021.1962485 · Cited by 18
Orthodenticle homeobox OTX1 is a potential prognostic biomarker for bladder cancer
Jiang, L., Zuo, Z., Lin, J., & Yang, C. (2021) · Bioengineered · doi:10.1080/21655979.2021.1974646 · Cited by 18
Agenant, M., van Dijk, T., Onur, A. R., Grimbergen, M. C. M., van Melick, H., Jonges, T. G. N., Bosch, J. L. H. R., & van Swol, C. F. P. (2022) · Journal of Biophotonics · doi:10.1002/jbio.202100354 · Cited by 18
Sun, M., Liu, X., Zhao, W., Zhang, B., & Deng, P. (2022) · BMC Cancer · doi:10.1186/s12885-022-09419-1 · Cited by 18
Kim, H., Roh, Y., Park, S. Y., Lee, C., Lim, S., Cho, S., Lee, H., Hong, S. A., Lee, T. J., Myung, S. C., et al. (2022) · Food Research International · doi:10.1016/j.foodres.2022.111144 · Cited by 19
Cai, H., Haifei, X., Lu, H., Xu, W., Liu, H., Wang, X., Zhou, G., & Yang, X. (2022) · Cancers · doi:10.3390/cancers14194740 · Cited by 18
Huang, Z., Wang, H., & Ji, Z. (2022) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22520 · Cited by 18
DHCR24 predicts poor clinicopathological features of patients with bladder cancer
Liu, X., Yin, X., Meng, X., Yan, X., Cao, Y., Zeng, X., & Wang, X. (2018) · Medicine · doi:10.1097/md.0000000000011830 · Cited by 18
Biomarkers in Non-Schistosomiasis-related squamous cell carcinoma of the urinary bladder: A review
Maia, M. C., Hansen, A. R., Alves, C., & Salah, S. H. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.01.008 · Cited by 18
Metadata
- Authors
- Antoni, S., Ferlay, J., Soerjomataram, I., Znaor, A., Jemal, A., & Bray, F.
- Affiliations
- Centre international de recherche sur le cancer (FR)
- American Cancer Society (US)
- Corresponding author
- Bray, Freddie
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 71
- Issue
- 1
- Pages
- 96-108
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2473162054
- Cited by
- 2,514
- References
- 55
- Citations by year
- 2026: 79 · 2025: 165 · 2024: 248 · 2023: 244 · 2022: 314 · 2021: 414 · 2020: 400 · 2019: 306 · 2018: 225 · 2017: 102
- FWCI
- 21.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Urology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- World Health Organization
- Topics
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Surgery › Urinary and Genital Oncology Studies
- Keywords
- bladder cancer, cancer incidence, cancer mortality, incidence trends, sex differences, smoking, Schistosoma haematobium, etiology, global cancer statistics
- MeSH terms
- Urinary Bladder Neoplasms, Female, Humans, Male, Registries, Risk Factors, Smoking, Global Health, Incidence, Internationality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
